Xellia Pharmaceuticals Inc.
Xellia Pharmaceuticals Inc., a leading global provider of specialty pharmaceuticals, is headquartered in the United States. Founded in 1908, the company has established a strong presence in the development and manufacturing of anti-infective and injectable products, primarily focusing on critical care and hospital settings. With operational facilities in Europe and North America, Xellia is renowned for its expertise in producing high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. The company’s core offerings include a range of injectable antibiotics and antifungal medications, distinguished by their efficacy and safety profiles. Xellia's commitment to innovation and quality has positioned it as a trusted partner in the healthcare industry, achieving notable milestones such as regulatory approvals and strategic collaborations. With a robust market presence, Xellia Pharmaceuticals continues to advance its mission of improving patient outcomes worldwide.
DitchCarbon Score
How does Xellia Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xellia Pharmaceuticals Inc.'s score of 23 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xellia Pharmaceuticals Inc.'s reported carbon emissions
Xellia Pharmaceuticals Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the absence of data does not preclude the company from engaging in climate commitments or initiatives within the pharmaceutical industry. As the sector increasingly focuses on sustainability, Xellia may be exploring strategies to enhance its environmental performance and align with industry standards. Further information on their climate commitments or future targets would be necessary to provide a comprehensive overview of their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Xellia Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
